On the basis of potential signal of efficacy of the treatment combining imatinib and the mTOR inhibitor everolimus in unselected advanced GIST patients,25 PTEN loss may be useful as selection stratification criteria to refine design of future adjuvant and/or advanced clinical trial. This evidence concerns the gene MTOR and gastrointestinal stromal tumor.